SecBot SecBot
SECBOTREPLAY Home › Report › OTLK

OTLK · Analysis based on filing metadata only, document content was…

Outlook Therapeutics, Inc. · 8-K filed Mar 11, 2026 at 17:16 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Mar 11, 2026 at 17:16 ET

Analysis based on filing metadata only, document content was unavailable. The filing reports a departure or appointment of an officer or director (Item 5.02) and includes financial statements or exhibits (Item 9.01), but no specific details or financial impact can be determined without the full document.

  • Filing is an 8-K report for Outlook Therapeutics, Inc. (OTLK)
  • Items disclosed: 5.02 (Departure/Appointment of Directors or Officers) and 9.01 (Financial Statements and Exhibits)
  • No document content available to assess specifics of executive change or nature of exhibits

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access